December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Exelixis, Inc. - Common Stock (NQ:EXEL)

42.47 +0.52 (+1.24%)
Streaming Delayed Price Updated: 10:48 AM EDT, Mar 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2
...
15 16 17 18 19 20 21 22 Next >
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 18, 2022 ↗
Upgrades 
Via Benzinga
News headline image
The Smartest Stocks to Buy With $20 Right Now ↗
Cheap stocks have the ability to generate enormous, long-term profits for investors. 
Via The Motley Fool
News headline image
Exelixis Announces Detailed Results From Late-Stage Cabometyx Combo Trial In Kidney Cancer ↗
 
Via Benzinga
News headline image
Recap: Exelixis Q2 Earnings ↗
  Exelixis (NASDAQ:EXEL) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:05 PM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Exelixis Handily Beats Second-Quarter Expectations, Retains 2022 Outlook ↗
Exelixis stock was flat immediately after the earnings release. 
Via Investor's Business Daily
News headline image
These 7 Biotech Stocks Are Set to Boom in 2023 ↗
This article looks at seven biotech stocks that look like good options to move significantly higher in 2023 
Via InvestorPlace
News headline image
Exelixis Expands Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Include the Fixed-Dose Combination of Nivolumab and Relatlimab in Combination with XL092 in Phase 1b STELLAR-002 Trial
From Exelixis, Inc.
Via Business Wire
News headline image
3 Biotech Stocks to Buy Now for Extraordinary Gains ↗
These biotech stocks should deliver big gains to long-term investors who purchase shares at a discount during the bear market. 
Via InvestorPlace
News headline image
Exelixis-BioInvent Establish Immuno-Oncology Pact ↗
 
Via Benzinga
News headline image
Exelixis' XL092/ Atezolizumab Shows Encouraging Efficacy, Safety In Heavily Pretreated Cancer Patients ↗
 
Via Benzinga
News headline image
Exelixis Announces Dose-Escalation Results from the Phase 1 STELLAR-001 Trial Evaluating XL092 Alone and in Combination with an Immune Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ESMO 2022
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis Announces Detailed Results from Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated Advanced Kidney Cancer at ESMO 2022
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis To Webcast Fireside Chats as Part of Investor Conferences in September
From Exelixis, Inc.
Via Business Wire
News headline image
Stock Market Rally Rises On Inflation Data; Nvidia, Micron, Tesla, Disney In Focus: Weekly Review ↗
The major indexes continued to advance, despite some key warnings. 
Via Investor's Business Daily
News headline image
Exelixis Announces Second Quarter 2022 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
News headline image
Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Exelixis to Release Second Quarter 2022 Financial Results on Tuesday, August 9, 2022
From Exelixis, Inc.
Via Business Wire
News headline image
7 Undervalued Biotech Stocks to Buy Before They Boom ↗
Despite recession fears, biological sciences will never go out of style, thus benefitting these undervalued biotech stocks to buy. 
Via InvestorPlace
News headline image
Exelixis Announces Cabozantinib in Combination with Nivolumab and Ipilimumab Significantly Improved Progression-Free Survival in Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated Advanced Kidney Cancer
From Exelixis, Inc.
Via Business Wire
News headline image
7 Best Biotech Stocks to Buy in July 2022 ↗
The best biotech stocks to buy are a lot like the best computer stocks 40 years ago; the biggest similarity is how hard they are to predict. 
Via InvestorPlace
News headline image
The Daily Biotech Pulse: Merck's Seagen Buyout Advances, Adverum Restructures, Pharmacists Get OK To Prescribe Pfizer COVID-19 Pill ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Exelixis and Ryvu Therapeutics Establish Exclusive License Agreement to Develop Novel STING Agonist-Based Targeted Cancer Therapies
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis to Webcast Fireside Chat as Part of the William Blair Biotech Focus Conference
From Exelixis, Inc.
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For June 24, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Recap of Tuesday's Biotech Catalysts - End of the Day Summary ↗
Ionis (NASDAQ: IONS) announced that Eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid... 
Via Benzinga
News headline image
Exelixis Announces Initiation of the STELLAR-303 Phase 3 Pivotal Trial Evaluating XL092 in Patients with Metastatic Colorectal Cancer
From Exelixis, Inc.
Via Business Wire
News headline image
The Daily Biotech Pulse: Roche's Alzheimer's Drug Fails, Advisors Back Pfizer, Moderna Shots For Youngest Kids, Valneva Settles COVID-19 Pact With UK ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Exelixis and BioInvent Establish Exclusive Option and License Agreement to Develop Novel Antibody-Based Immuno-Oncology Therapies
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis To Webcast Fireside Chats as Part of Investor Conferences in June
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis Announces Detailed Results from Urothelial Carcinoma and Non-Small Cell Lung Cancer Cohorts of the COSMIC-021 Trial at ASCO 2022
From Exelixis, Inc.
Via Business Wire
< Previous 1 2
...
15 16 17 18 19 20 21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.